Rapport Therapeutics, Inc. (RAPP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 8, 2025, by Rapport Therapeutics, Inc., a Delaware corporation. The filing discloses positive topline results from the Phase 2a clinical trial of RAP-219 for the treatment of drug-resistant focal onset seizures. The company is an emerging growth company listed on the Nasdaq Global Market.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The primary material event is the announcement of statistically significant efficacy results from the Phase 2a trial (RAP-219-FOS-201) over an 8-week treatment period.
Efficacy Outcomes
- Long Episodes (LEs) - Primary Endpoint: 85.2% of patients achieved a ≥30% reduction from baseline (p<0.0001). The median reduction in LE frequency was 71.0% (p=0.0001).
- Clinical Seizures (CS) - Key Secondary Endpoint: 72.0% of patients achieved a ≥50% reduction from baseline (p<0.0001). 24.0% of patients achieved seizure freedom (p<0.0001). The median reduction in clinical seizure frequency was 77.8% (p=0.01).
Safety and Tolerability
- Population: 30 patients entered the treatment period; 4 discontinued (3 due to treatment-emergent adverse events).
- Severity: No serious adverse events were reported. All TEAEs were mild (78.5%) or moderate (21.5%).
- Common TEAEs (≥10% incidence): Dizziness (26.7%), headache (16.7%), fatigue (13.3%), fall (10.0%), nausea (10.0%), and somnolence (10.0%).
Guidance, Outlook, and Risks
Management outlined the following development plans and timelines:
- Regulatory Interaction: End-of-Phase 2 meeting with the FDA planned for Q4 2025.
- Follow-up Data: 8-week follow-up results expected in 2026.
- Long-Term Safety: Open-label trial initiation planned by end of 2025; preliminary results expected H2 2026.
- Phase 3 Pivotal Trials: Planned initiation in Q3 2026.
- Formulation Development: Long-acting injectable (LAI) pharmacokinetic results expected in 2027.
- Other Indications: Phase 2 trial in bipolar mania is enrolling (topline results H1 2027); update on diabetic peripheral neuropathic pain trial expected later in 2025.
Risks: The filing includes standard forward-looking statement disclaimers. Key risks include the ability to execute the development strategy, obtain regulatory approvals, secure additional funding, and manage clinical trial uncertainties.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and the corporate presentation (Exhibit 99.2) for detailed statistical methodologies and patient demographics.
- Confirm the company's current cash runway and capital requirements in the most recent Form 10-Q or 10-K, as this 8-K does not provide financial data.
- Monitor the outcome of the planned end-of-Phase 2 meeting with the FDA in Q4 2025 for regulatory feedback on the Phase 3 design.
- Review the safety profile details regarding the 10% discontinuation rate due to adverse events in the context of long-term treatment plans.